🍽️ betamethasone,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Skin Conditions:

    • Eczema (atopic dermatitis)
    • Psoriasis
    • Contact dermatitis (allergic or irritant)
    • Seborrheic dermatitis
    • Dermatitis herpetiformis
    • Lichen planus
    • Discoid lupus erythematosus
    • Prurigo nodularis
    • Cutaneous T-cell lymphoma (Mycosis fungoides)
    • Generalized erythroderma
  2. Inflammatory Conditions:

    • Allergic reactions
    • Insect bites or stings
    • Severe allergic rhinitis
    • Angioedema
    • Stevens-Johnson syndrome
    • Toxic epidermal necrolysis
  3. Joint and Musculoskeletal Disorders:

    • Rheumatoid arthritis
    • Osteoarthritis
    • Bursitis
    • Tenosynovitis
    • Tendonitis
  4. Respiratory Conditions:

    • Asthma (in severe cases)
    • Allergic rhinitis
    • Chronic obstructive pulmonary disease (COPD)
    • Pulmonary sarcoidosis
  5. Inflammatory Eye Conditions:

    • Allergic conjunctivitis
    • Uveitis
    • Keratitis
    • Iritis
  6. Inflammatory Bowel Disease (Off-label):

    • Ulcerative colitis
    • Crohn's disease (in some cases)
  7. Certain Types of Cancer (as part of chemotherapy regimen):

    • Leukemia (e.g., acute lymphoblastic leukemia)
    • Lymphomas
    • Multiple myeloma
  8. Fetal Lung Maturation (Antenatal Use):

    • Betamethasone may be administered to pregnant women at risk of preterm delivery to accelerate fetal lung maturation and reduce the risk of respiratory distress syndrome in premature infants.
;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of betamethasone,(prescription) On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
species Lacticaseibacillus paracasei Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by betamethasone,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Roseburia genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Blautia genus Decreases 👪 Source Study
Eggerthella genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Veillonella genus Decreases 👪 Source Study
Lachnospira genus Decreases 👪 Source Study
Odoribacter genus Decreases 👪 Source Study
Clostridioides genus Decreases 👪 Source Study
Clostridium genus Decreases 👪 Source Study Pathogen
Enterocloster genus Decreases 👪 Source Study
Phocaeicola genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Akkermansia genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Roseburia hominis species Decreases 📓 Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Bifidobacterium adolescentis species Decreases 📓 Source Study
Blautia obeum species Decreases 📓 Source Study
Eggerthella lenta species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Bifidobacterium longum species Decreases 📓 Source Study
Bacteroides caccae species Decreases 📓 Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
Veillonella parvula species Decreases 📓 Source Study
Bacteroides ovatus species Decreases 📓 Source Study
Lachnospira eligens species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Odoribacter splanchnicus species Decreases 📓 Source Study
Clostridioides difficile species Decreases 📓 Source Study Colitis
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Enterocloster bolteae species Decreases 📓 Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Dorea formicigenerans species Decreases 📓 Source Study
Akkermansia muciniphila species Decreases 📓 Source Study
Agathobacter rectalis species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of betamethasone,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Acne 0.2 -0.2
ADHD 1.8 0.2 8
Age-Related Macular Degeneration and Glaucoma 0.4 0.4
Allergic Rhinitis (Hay Fever) 0.2 1.1 -4.5
Allergies 1.5 0.6 1.5
Allergy to milk products 0.2 0.2 0
Alopecia (Hair Loss) 0.4 0.4
Alzheimer's disease 0.6 2.7 -3.5
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.6 0 0
Ankylosing spondylitis 0.8 0.3 1.67
Anorexia Nervosa 0.9 -0.9
Antiphospholipid syndrome (APS) 0.2 0.2
Asthma 0.7 0.6 0.17
Atherosclerosis 0.4 0.6 -0.5
Atrial fibrillation 0.9 0.4 1.25
Autism 2.9 2.5 0.16
Barrett esophagus cancer 0.1 0.1
Bipolar Disorder 0.2 0.7 -2.5
Brain Trauma 0.4 0.5 -0.25
Cancer (General) 0.1 1.9 -18
Carcinoma 1.1 0.9 0.22
Celiac Disease 0.5 1.4 -1.8
Cerebral Palsy 0.4 0.7 -0.75
Chronic Fatigue Syndrome 2.1 1.3 0.62
Chronic Kidney Disease 1.1 0.6 0.83
Chronic Lyme 0.5 -0.5
Chronic Obstructive Pulmonary Disease (COPD) 0.1 0.5 -4
Chronic Urticaria (Hives) 0.2 0 0
Coagulation / Micro clot triggering bacteria 0.6 -0.6
Colorectal Cancer 0.8 0.4 1
Constipation 0.4 0.6 -0.5
Coronary artery disease 0.2 0.4 -1
COVID-19 3.6 3.6 0
Crohn's Disease 1.7 1.6 0.06
cystic fibrosis 0.8 -0.8
deep vein thrombosis 0.4 -0.4
Depression 4 2.5 0.6
Dermatomyositis 0.2 -0.2
Eczema 0.1 0.3 -2
Endometriosis 0.6 0.3 1
Eosinophilic Esophagitis 0.1 -0.1
Epilepsy 0.8 0.6 0.33
Fibromyalgia 0.7 0.5 0.4
Functional constipation / chronic idiopathic constipation 1.3 1.8 -0.38
gallstone disease (gsd) 0.5 0.6 -0.2
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.2 0.4 -1
Generalized anxiety disorder 0.2 0.9 -3.5
giant cell arteritis 0.1 -0.1
Graves' disease 0.6 0.8 -0.33
Halitosis 0.3 0.3
Hashimoto's thyroiditis 1.7 0.4 3.25
Hidradenitis Suppurativa 0.1 -0.1
hypercholesterolemia (High Cholesterol) 0.2 0 0
hyperglycemia 0.6 -0.6
Hyperlipidemia (High Blood Fats) 0.4 0.2 1
hypersomnia 0.2 -0.2
hypertension (High Blood Pressure 0.6 2.4 -3
Hypothyroidism 0.6 -0.6
Hypoxia 0.2 0.2
IgA nephropathy (IgAN) 0.9 -0.9
Inflammatory Bowel Disease 0.8 1.9 -1.37
Insomnia 0.4 0.6 -0.5
Intelligence 0.1 0.1
Intracranial aneurysms 0.4 0.2 1
Irritable Bowel Syndrome 1.5 1.4 0.07
Liver Cirrhosis 1.3 1 0.3
Long COVID 2.1 3.4 -0.62
Low bone mineral density 0.5 -0.5
Lung Cancer 0.3 0.3 0
Mast Cell Issues / mastitis 0.2 -0.2
ME/CFS with IBS 0.2 0.9 -3.5
ME/CFS without IBS 0.8 0.5 0.6
Menopause 1.1 1.1
Metabolic Syndrome 2.2 3 -0.36
Mood Disorders 4.6 2.7 0.7
multiple chemical sensitivity [MCS] 0.2 0.2 0
Multiple Sclerosis 1.5 1 0.5
Multiple system atrophy (MSA) 0.7 0.4 0.75
neuropathic pain 1.1 -1.1
Neuropathy (all types) 0.2 0.2
neuropsychiatric disorders (PANDAS, PANS) 0.1 0.1
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.5 2.1 -3.2
NonCeliac Gluten Sensitivity 0.2 -0.2
Obesity 3.5 1.3 1.69
obsessive-compulsive disorder 1.4 1.4 0
Osteoarthritis 0.2 0.2
Osteoporosis 0.6 0.4 0.5
pancreatic cancer 0.1 0.1
Parkinson's Disease 0.6 0.8 -0.33
Polycystic ovary syndrome 0.6 0.8 -0.33
Postural orthostatic tachycardia syndrome 0.1 0.2 -1
Premenstrual dysphoric disorder 0.6 0.6
primary biliary cholangitis 0 0.2 0
Psoriasis 1 0.5 1
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 1.8 1.2 0.5
Rosacea 0.9 0.4 1.25
Schizophrenia 2.4 0.9 1.67
scoliosis 0.2 -0.2
Sjögren syndrome 0.7 1.2 -0.71
Sleep Apnea 0.4 0.9 -1.25
Small Intestinal Bacterial Overgrowth (SIBO) 0.4 -0.4
Stress / posttraumatic stress disorder 0.9 1.3 -0.44
Systemic Lupus Erythematosus 0.8 1 -0.25
Tic Disorder 0.2 0.4 -1
Tourette syndrome 0 0.2 0
Type 1 Diabetes 0.9 1.1 -0.22
Type 2 Diabetes 2.2 1.5 0.47
Ulcerative colitis 0.9 1.3 -0.44
Unhealthy Ageing 1.6 0.7 1.29

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [44.222.64 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [44.222.64 ]